Table 4B. Acute (14-day) toxicity of 89Zr-DFO-nimotuzumab.
| Parameters | Male ± Std Dev. | Female ± Std Dev. | ||
|---|---|---|---|---|
| Clinical chemistry | Control treated | 89Zr-DFO-nimotuzumab | Control treated | 89Zr-DFO-nimotuzumab |
| Albumin:Globulin (g/L) | 1.37 ± 0.23 | 1.49 ± 0.07 | 2.19 ± 0.21 | 1.94 ± 0.15 |
| Albumin (g/L) | 27.40 ± 3.36 | 29.0 ± 1.41 | 31.80 ± 0.84 | 31.40 ± 28.43 |
| Globulin (g/L) | 20.21 ± 1.64 | 19.4 ± 0.89 | 14.60 ± 1.14 | 16.2 ± 0.83 |
| Alkaline Phosphatase (U/L) | 106.60 ± 11.72 | 108.2 ± 4.42 | 127.60 ± 2.30 | 115.6 ± 4.61 |
| ALT (U/L) | 35.4 ± 8.79 | 27.40 ± 1.14 | 26.20 ± 3.56 | 23.60 ± 2.70 |
| AST (U/L) | 233.4 ± 143.3 | 71.0 ± 11.29 | 78.80 ± 12.48 | 103.80 ± 28.43 |
| Bicarbonate (mmol/L) | 15.81 ± 2.49 | 18.4 ± 1.51 | 15.21 ± 1.48 | 16.01 ± 1.58 |
| Ca2+ (mmol/L) | 2.35 ± 0.13 | 2.36 ± 0.10 | 2.27 ± 0.09 | 2.27 ± 0.03 |
| Cl−1 (mmol/L) | 104.6 ± 3.36 | 106.6 ± 1.52 | 107.2 ± 2.58 | 107.0 ± 1.58 |
| Creatinine | 13.4 ± 1.82 | 14.60 ± 2.70 | 12.8 ± 0.84 | 13.8 ± 2.0 |
| Glucose (mmol/L) | 12.22 ± 1.37 | 11.89 ± 0.61 | 11.42 ± 0.85 | 11.62 ± 2.27 |
| K+ (mmol/L) | 6.20 ± 1.06 | 5.18 ± 0.33 | 4.52 ± 0.47 | 4.30 ± 0.50 |
| Na+ (mmol/L) | 147.40 ± 4.39 | 149.6 ± 1.52 | 148.0 ± 1.87 | 147.4 ± 0.89 |
| Na+/Ka+ | 24.40 ± 5.03 | 29.0 ± 2.0 | 32.81 ± 4.03 | 34.80 ± 3.7 |
| Total bilirubin (μmol/L) | 1.32 ± 0.33 | 0.62 ± 0.24 | 0.82 ± 0.18 | 1.02 ± 0.33 |
| Total protein (g/L) | 47.6 ± 2.4 | 48.4 ± 1.95 | 46.41 ± 1.14 | 47.60 ± 0.54 |
| Urea (mmol/L) | 7.48 ± 0.39 | 9.52 ± 0.93 | 7.48 ± 0.39 | 9.52 ± 0.93 |
| Cell Blood Counts | ||||
| HCT (L/L) | 0.46 ± 0.02 | 0.47 ± 0.03 | 0.47 ± 0.01 | 0.47 ± 0.01 |
| HGB (g/L) | 147.40 ± 5.22 | 148.3 ± 6.75 | 148.60 ± 4.04 | 150.60 ± 4.34 |
| MCH (pg) | 15.04 ± 0.20 | 15.35 ± 0.13 | 15.30 ± 0.14 | 15.66 ± 0.27 |
| MCHC (g/L) | 317.40 ± 5.68 | 311.30 ± 7.6 | 313.80 ± 5.93 | 318.4 ± 6.22 |
| MCV (fL) | 47.46 ± 0.41 | 49.33 ± 1.68 | 48.76 ± 0.65 | 49.18 ± 0.59 |
| RBC (x1012/L) | 9.8 ± 0.41 | 9.66 ± 0.49 | 9.71 ± 0.25 | 9.61 ± 0.33 |
| RDW (%) | 13.66 ± 0.11 | 14.73 ± 0.29 | 14.24 ± 0.25 | 14.64 ± 0.25 |
| WBC (x109/L) | 1.92 ± 1.22 | 2.18 ± 0.71 | 2.14 ± 1.12 | 1.25 ± 0.06 |
* (male) and ** (female): There were no significant differences in all parameters between control treated and 89Z-DFO-nimotuzumab treated mice following injection of excess of 89Zr-DFO-nimotuzumab.